Breaking News, Collaborations & Alliances

AbbVie, Capsida Expand Strategic Pact to Develop Genetic Medicines for Eye Diseases

Partnership combines AbbVie’s extensive capabilities with Capsida’s novel adeno-associated virus (AAV) engineering platform.

AbbVie and Capsida Biotherapeutics Inc. have expanded a strategic collaboration to develop genetic medicines for eye diseases with high unmet need. AbbVie’s extensive capabilities will be paired with Capsida’s novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs. The collaboration builds upon the neurodegenerative disease partnership announced in 2021. “This expanded collaboration with Capsida has the potential to devel...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters